Published in final edited form as:

Methods Mol Biol. 2014 ; 1165: 115–143. doi:10.1007/978-1-4939-0856-1_10.

Methods for the Study of Long Noncoding RNA in Cancer Cell Signaling

Yi Feng, Xiaowen Hu, Youyou Zhang, Dongmei Zhang, Chunsheng Li, and Lin Zhang

Abstract

With the advances in sequencing technology and transcriptome analysis, it is estimated that up to 75 % of the human genome is transcribed into RNAs. This finding prompted intensive investigations on the biological functions of noncoding RNAs and led to very exciting discoveries of microRNAs as important players in disease pathogenesis and therapeutic applications. Research on long noncoding RNAs (lncRNAs) is in its infancy, yet a broad spectrum of biological regulations has been attributed to lncRNAs. Here, we provide a collection of detailed experimental protocols for lncRNA studies, including lncRNA immunoprecipitation, lncRNA pull-down, lncRNA northern blot analysis, lncRNA in situ hybridization, and lncRNA knockdown. We hope that the information included in this chapter can speed up research on lncRNAs biology and eventually lead to the development of clinical applications with lncRNA as novel prognostic markers and therapeutic targets.

Keywords

Long noncoding RNA; RNA immunoprecipitation; RNA pull-down; In situ hybridization; Northern blot; Short hairpin RNA

1 Introduction

Cancer is a genetic disease involving multistep changes in the genome [1]. While up to 75 % of the human genome is transcribed to RNA, only less than 2 % of the genome encodes protein-coding transcripts, leaving most of the genome to noncoding RNA transcripts [2, 3]. The recent discovery of the noncoding RNA genes has dramatically altered our understanding of cancer genetics. In the last decade, the functional significance of small noncoding RNA and microRNA in tumorigenesis and progression has been extensively documented; yet research on long noncoding RNA (lncRNA) is still in its infancy [4–8]. lncRNAs are operationally defined as RNA genes larger than 200 bp that do not appear to have protein coding potential [4–8]. Recent studies demonstrated that lncRNAs act as key regulators of development, differentiation, apoptosis, and cell proliferation, all of which have been implicated in tumor initiation and progression. In addition, the expression of lncRNAs has been found to be remarkably deregulated by epigenetic and genomic alterations in tumors. In various experimental systems, lncRNAs have been reported to have tumor suppressor or oncogene activity. Therefore, it is reasoned that lncRNAs may play

important roles in the development of cancer, hence represent the leading edge of cancer research. Investigations on lncRNA functions in cancer will lead to a greater understanding of molecular mechanisms of this disease, and eventually lead to the development of lncRNA-based novel applications in cancer diagnosis and therapeutic management.

1.1 The Human Genome Contains Many Thousands of Unexplored lncRNAs

lncRNAs are operationally defined as RNA transcripts larger than 200 bp that do not appear to have coding potential [4–8]. Given that up to 75 % of the human genome is transcribed to RNA, while only a small portion of the transcripts encodes proteins [3], the number of lncRNA genes can be large. After the initial cloning of functional lncRNAs such as H19 [9, 10] and XIST [11] from cDNA libraries, two independent studies using high-density tiling array reported that the number of lncRNA genes is at least comparable to that of protein-coding genes [12, 13]. Recent advances in tiling array [12–15], chromatin signature [16, 17], computational analysis of cDNA libraries [18, 19], and next-generation sequencing (RNA-seq) [20–23] have revealed that thousands of lncRNA genes are abundantly expressed with exquisite cell-type and tissue specificity in human. In fact, the GENCODE consortium within the framework of the ENCODE project recently reported 14,880 manually annotated and evidence-based lncRNA transcripts originating from 9,277 gene loci in human [3, 23], including 9,518 intergenic lncRNAs (also called lincRNAs) and 5,362 genic lncRNAs (Fig. 1a) [16, 17, 22]. These studies indicate that (1) lncRNAs are independent transcriptional units; (2) lncRNAs are spliced with fewer exons than protein-coding transcripts and utilize the canonical splice sites; (3) lncRNAs are under weaker selective constraints during evolution and many are primate specific; (4) lncRNA transcripts are subjected to typical histone modifications as protein-coding mRNAs; and (5) the expression of lncRNAs is relatively low and strikingly tissue-specific or cell-type-specific.

1.2 lncRNAs Regulate Gene Expression and Protein Functions via Various Mechanisms

The discovery of lncRNA has provided an important new perspective on the centrality of RNA in gene expression regulation. lncRNAs can regulate the transcriptional activity of a chromosomal region or a particular gene by recruiting epigenetic modification complexes in either *cis*- or *trans*-regulatory manner. For example, Xist, a 17 kb X-chromosome specific noncoding transcript, initiates X chromosome inactivation by targeting and tethering Polycomb-repressive complexes (PRC) to X chromosome in *cis* [24–26]. HOTAIR regulates the HoxD cluster genes in *trans* by serving as a scaffold, which enables RNA-mediated assembly of PRC2 and LSD1 and coordinates the binding of PRC2 and LSD1 to chromatin [14, 27]. Based on the knowledge obtained from studies on a limited number of lncRNAs, at least two working models have been proposed (Fig. 1b). First, lncRNAs can function as scaffolds. lncRNAs contain discrete protein-interacting domains that can bring specific protein components into the proximity of each other, resulting in the formation of unique functional complexes [27–29]. These RNA mediated complexes can also extend to RNA–DNA and RNA–RNA interactions. Second, lncRNAs can act as guides to recruit proteins [26, 30, 31], such as chromatin modification complexes, to chromosome [26, 31]. This may occur through RNA–DNA interactions [31] or through RNA interaction with a DNA-binding protein [26]. In addition, lncRNAs have been proposed to serve as decoys that bind to DNA-binding proteins [32], transcription factors [33], splicing factors [34–36], or

miRNAs [37]. Some studies have also identified lncRNAs transcribed from the enhancer regions [38–40] or a neighborloci [20, 41] of certain genes. Given that their expressions correlated with the activities of the corresponding enhancers, it was proposed that these RNAs (termed enhancer RNA/eRNA [38–40] or ncRNA-activating/ncRNA-a [20, 41]) may regulate gene transcription.

1.3 lncRNA Expression Is Deregulated in Human Cancer

The advances in high-throughput RNA quantification technologies unveiled a profound deregulation of the lncRNome in human cancer. First, lncRNA expression profiles are dramatically different between tumors and their adjacent normal tissues. A large-scale RNA-seq analysis in prostate cancer identified 121 lncRNAs whose expressions pattern can distinguish between benign and cancer specimens [21]. Second, given that lncRNA expression patterns are more tissue-specific than those of protein coding genes [22, 23], it has been proposed that lncRNA expression signatures may be able to accurately determine the developmental lineage and tissue origin of human cancers. Third, the association between the expressions of several lncRNAs, such as MALAT-1 [42], HOTAIR [15], PCAT-1 [21] and LET [43], and cancer metastasis have been identified by high-throughput profiling studies and validated by further independent investigations, suggesting that lncRNAs may also serve as robust biomarkers in predicting cancer prognosis and survival.

1.4 lncRNAs Serve as Tumor Suppressor Genes or Oncogenes

Though studies on lncRNAs are still in their early stage, it is clear that lncRNAs are involved in regulating proliferation [33, 36], differentiation [16, 31, 44–46], migration [15, 20], and apoptosis [30, 47]. Therefore, it is reasoned that deregulation of lncRNA expression may contribute to the development and progression of cancer. In fact, some lncRNAs have been shown to function as oncogenes or tumor suppressors. For example, HOTAIR [14] can induce metastasis [15] by operating as a tether that links EZH2/PRC2 and LSD1, and therefore coordinating their epigenetic regulatory functions [27]. ANRIL, an antisense lncRNA of the CDKN2A/CDKN2B gene, represses INK4A/INK4B expression [48] by binding to CBX7/PRC1 [28] and SUZ12/PRC2 [29]. On the other hand, deleting Xist resulted in the development of highly aggressive myeloproliferative neoplasm and myelodysplastic syndrome with 100 % penetrance in female mice [49].

1.5 lncRNAs Represent Promising Biomarker and Therapeutic Candidates for Cancer Diagnosis and Treatment

The ability to fully characterize cancer genome contributed significantly to the development of biomarkers and therapeutic applications for cancer diagnoses and treatments. PCA3, a prostate cancer-associated lncRNA [50], is the first prominent example of lncRNA as a novel biomarker. The noninvasive method to detect PCA3 transcript in urine has been developed and used clinically to detect prostate malignancy [51]. The transition from lncRNA-based diagnostics to lncRNA-based therapies is also under intensive investigations. The rapid advances in oligonucleotide/nanoparticle therapy create realistic optimism for developing lncRNA-based therapeutic tools for cancer treatment. Although the majority of cancer-related studies still focus on the protein-coding genes, given that almost 75 % of the genome is transcribed to RNAs and initial studies on a handful of lncRNAs clearly

demonstrated their functional significance in cancer development and high potential in clinical applications, we argue that investigations on lncRNAs is the leading edge of cancer research.

1.6 Methods in lncRNAs Research

In the following sections, we provide detailed protocols on characterizing lncRNA expression and functions. They are RNA-immunoprecipitation (RNA-IP), RNA pull-down, northern blot analysis on lncRNA expression, In situ hybridization (ISH) of lncRNA and lncRNA knockdown, respectively. As one major mechanism for lncRNA to exert its function is to serve as a scaffold via RNA–protein interaction, it is important to investigate which lncRNAs are binding to a protein of interest. RNA-IP has been developed to identify lncRNA species that bind to a protein of interest. On the other hand, if the research focus is to identify the proteins that are bound to a given lncRNA, lncRNA pull-down will help to identify the protein molecules that interact with a specific lncRNA (Fig. 2). Moreover, as a novel class of RNA transcripts, it is important to characterize the expression of lncRNAs in various systems. While the northern blot can be used to determine lncRNA abundance and to identify different splicing variants of a given lncRNA, lncRNA in situ hybridization can also provide information regarding the expression level of a given lncRNA. More importantly, it can reveal the cellular or tissue localization of the lncRNA of interest. Knocking down the expression of a target gene has been a gold standard assay to elucidate its endogenous function. In this regard, we also included two lncRNA knockdown protocols in this chapter. We hope this chapter would help the readers to develop assays for their lncRNA research, which will lead to a better understanding of the roles of lncRNAs in carcinogenesis and other pathological conditions.

2 Materials

Prepare all solutions using ultrapure RNase-free water and analytical grade reagents. Contamination of the solutions with RNase can result in RNA degradation. Use filtration or/and autoclave sterilization to ensure that all reagents and supplies used in this section are RNase free. Use RNase ZAP to clean all equipment and work surface.

2.1 lncRNA-IP

1. M Dithiothreitol (DTT).
2. 10× Phosphate-Buffered Saline (PBS): 1.37 μM NaCl, 27 mM KCl, 100 mM Na₂HPO₄, 20 mM KH₂PO₄, pH 7.4, sterilize. To make 1× PBS, mix one part of 10× PBS with nine parts RNase-free water. Store at 4 °C.
3. Protein A/G beads.
4. RNase inhibitor (Invitrogen).
5. Protease inhibitor cocktail (Sigma).
6. TRIzol RNA extraction reagent (Invitrogen).
7. 1 mL Dounce homogenizer.

8. Nuclear Isolation Buffer: 1.28 M sucrose, 40 mM Tris–HCl (pH 7.4), 20 mM MgCl₂, 4 % Triton X-100. Put 40 mL RNase-free water in a beaker with a stir bar and dissolve 21.9 g sucrose in the beaker. Add 2 mL 1 M Tris–HCl (pH 7.5), 1 mL 1 M MgCl₂, and 2 mL Triton X-100 and mix well. Make up to a final volume of 50 mL with RNase-free water, store at 4 °C.
9. RNA Immunoprecipitation (RIP) Buffer: 150 mM KCl, 25 mM Tris (pH 7.4), 5 mM EDTA, 0.5 % NP-40. Mix 7.5 mL 1 M KCl, 1.25 mL 1 M Tris–HCl (pH 7.4), 500 µL 0.5 M EDTA, and 250 µL NP-40 and make up to a final volume of 48 mL with RNase-free water. Store at 4 °C. Right before use, add DTT (0.5 mM final concentration), RNase inhibitor (100 U/mL final concentration), and protease inhibitor cocktail (1× final concentration).

2.2 Materials for lncRNA Pull-Down

1. M Dithiothreitol (DTT).
2. 10× Phosphate-Buffered Saline (10× PBS: 1.37 µM NaCl, 27 mM KCl, 100 mM Na₂HPO₄, 20 mM KH₂PO₄, pH 7.4). To make 1× PBS, mix one part of 10× PBS with nine parts RNase-free water. Store at 4 °C.
3. DNA template (*see* Note 1).
4. Restriction Enzyme.
5. Vanadyl-ribonucleoside complex (VRC, NEB).
6. 10× Biotin RNA labeling mix (Roche).
7. T7 RNA polymerase (10 U/µL) and 5× transcription buffer (Agilent).
8. RNase inhibitor (Invitrogen).
9. Protease inhibitor cocktail (Sigma).
10. Dnase I, 2,000 U/mL (NEB).
11. Streptavidin Agarose Beads.
12. 0.5 M EDTA (pH 8.0).
13. Yeast tRNA (Ambion).
14. Nuclear Isolation Buffer: 1.28 M sucrose, 40 mM Tris–HCl (pH 7.4), 20 mM MgCl₂, 4 % Triton X-100. Put 40 mL RNase-free water in a beaker with a stir bar and dissolve 21.9 g sucrose in the beaker. Add 2 mL 1 M Tris–HCl (pH 7.5), 1 mL 1 M MgCl₂, and 2 mL Triton X-100 and mix well. Make up to a final volume of 50 mL with RNase-free water, store at 4 °C.

¹The desired DNA template should be a plasmid containing a promoter for in vitro transcription (i.e., T7 or T3) and a target sequence whose 5' end is placed as close as possible to the 3' end of the promoter. We usually use pBluescript SK(+) and transcribe the target sequence using T7 polymerase. Minimize any unnecessary addition of non-lncRNA sequence into the plasmid to avoid inappropriate RNA folding.

15. RNA Immunoprecipitation (RIP) Buffer: 150 mM KCl, 25 mM Tris (pH 7.4), 5 mM EDTA, 0.5 % NP-40. Mix 7.5 mL 1 M KCl, 1.25 mL 1 M Tris-HCl (pH 7.4), 500 μ L 0.5 M EDTA, and 250 μ L NP-40 and make up to a final volume of 48 mL with RNase-free water. Store at 4 °C. Right before use, add DTT (0.5 mM final concentration), RNase inhibitor (100 U/mL final concentration), and protease inhibitor cocktail (1 $\times$ final concentration).
16. NT2 Buffer: 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM MgCl₂, 0.05 % NP-40. Store at 4 °C. For 50 mL NT2 buffer, mix 2.5 mL 1 M Tris-HCl, 5 mL 150 mM NaCl, 1 mL 1 mM MgCl₂, 2.5 mL 1 % NP-40, add 39 mL RNase-free water to a final volume of 50 mL, filter stock solution, store at 4 °C. Right before use, add RNase inhibitor (100 U/mL final concentration), Vanadyl-ribonucleoside complex (VRC, 400 nM final concentration), DTT (1 mM final concentration), EDTA (20 mM final concentration), and protease inhibitor cocktail (1 $\times$ final concentration).
17. RNA structure buffer: 10 mM Tris (pH 7.0), 0.1 M KCl, 10 mM MgCl₂.
18. 1 mL Dounce homogenizer.
19. Agarose gel electrophoresis supplies for DNA fragment purification.
20. Quick Spin Columns for radiolabeled RNA purification Sephadex G-50 (Roche).
21. Gel Extraction Kit (Qiagen).
22. BCA protein assay kit (Pierce).
23. 2 $\times$ Laemmli loading buffer: 4 % SDS, 120 mM Tris-HCl (pH 6.8), 0.02 % bromophenol blue, and 0.2 M DTT. Mix 4 mL 10 % SDS, 1.2 mL 1 M Tris-HCl (pH 6.8), 200 μ L 1 % bromophenol blue, and 2 mL 1 M DTT and add Milli-Q water to make the final volume to 10 mL. Make 500 μ L aliquots to minimize the freeze-thaw cycles.

2.3 Materials for lncRNA Northern Blot Analysis

2.3.1 Digoxigenin (DIG)-Labeled RNA Probe Synthesis

1. DNA template (*see* Note 1).
2. Restriction Enzyme.
3. 10 $\times$ DIG RNA labeling mix (Roche).
4. T7 RNA polymerase (10 U/ μ L) and 5 $\times$ transcription buffer (Agilent).
5. Dnase I 2,000 U/mL (NEB).
6. Agarose gel electrophoresis supplies for DNA fragment purification.
7. Quick Spin Columns for radiolabeled RNA purification Sephadex G-50 (Roche).
8. Gel Extraction Kit (Qiagen).

2.3.2 Separating RNA by Electrophoresis

1. Nucleic acid agarose.

2. 55 °C water bath.
3. 10× Denaturing gel buffer (Invitrogen).
4. Heat block.
5. Gel electrophoresis apparatus.
6. 10× MOPS buffer: 200 mM MOPS, 50 mM Sodium acetate, 20 mM EDTA, adjust pH to 7.0. To make 1× MOPS gel running buffer, mix one part of 10× MOPS buffer with nine parts of RNase-free water.
7. RNA loading buffer (Invitrogen).
8. Ethidium bromide (only if RNA visualization is needed).
9. DIG-labeled RNA marker (Roche).

2.3.3 Transferring RNA to the Membrane

1. 20× SSC: 3 M NaCl (1.75 g/L), 0.3 M Sodium citrate dihydrate (88 g/L). Adjust pH to 7.0 with 1 M HCl.
2. Razor blade.
3. 3 M Filter paper.
4. Positively Charged Nylon Membrane (Roche).
5. Blunt end forceps.
6. Paper towel.
7. RNase-free flat-bottom container as buffer reservoir.
8. Clean glass Pasteur pipet as roller.
9. Light weight (150–200 g) object serving as weight during transfer.
10. Supports for the reservoir (i.e., a stack of books).
11. Stratalinker® UV Crosslinker.

2.3.4 Probe–RNA Hybridization

1. 20× SSC: 3 M NaCl (1.75 g/L), 0.3 M Sodium citrate dihydrate (88 g/L). Adjust pH to 7.0 with 1 M HCl.
2. 10 % SDS.
3. DIG Easy Hyb Granules (Roche).
4. 68 °C shaking water bath.
5. Heat block.
6. Hybridization oven.
7. Hybridization bags.

8. Low Stringency Buffer: 2× SSC with 0.1 % SDS.
9. High Stringency Buffer: 0.1× SSC with 0.1 % SDS.

2.3.5 Detection of Probe–RNA Hybrids

1. Washing and blocking buffer set (Roche).
2. Anti-DIG-alkaline phosphatase antibody (Roche).
3. NBT/BCIP Stock Solution (Roche).
4. CDP-Star, Ready-to-Use (Roche).
5. TE buffer: 10 mM Tris–HCL, 1 mM EDTA, adjust pH to approximately 8.

2.4 Materials for IncRNA In Situ Hybridization

1. 8-well chamber slide.
2. 10× Phosphate-Buffered Saline (10× PBS: 1.37 μM NaCl, 27 mM KCl, 100 mM Na₂HPO₄, 20 mM KH₂PO₄, pH 7.4). To make 1× PBS, mix one part of 10× PBS with nine parts RNase-free water. Store at 4 °C.
3. 4 % paraformaldehyde (in RNase-free PBS).
4. 0.1 M triethanolamine.
5. Acetic anhydride.
6. 0.2 M HCl in RNase-free water.
7. 20× SSC: 3 M NaCl (1.75 g/L), 0.3 M Sodium citrate dihydrate (88 g/L). Adjust pH to 7.0 with 1 M HCl.
8. 50× Denhardt solution (Sigma).
9. 50 % Dextran sulfate solution: dissolve 5 g Dextran sulfate in 10 mL RNase-free water, stir at room temperature until completely dissolved.
10. Yeast tRNA.
11. Pre-hybridization buffer: 2× SSC, 50 % formamide, 1× Denhardt solution, and 1 mg/mL yeast tRNA. For 50 mL hybridization buffer, add 1 mL 20× SSC, 5 mL formamide, 200 μL 50× Denhardt solution, and 50 mg yeast tRNA, and make up a final volume of 50 mL with RNase-free water.
12. Hybridization buffer: 2× SSC, 50 % formamide, 1× Denhardt solution, 10 % dextran sulfate, 1 mg/mL yeast tRNA. For 50 mL hybridization buffer, add 1 mL 20× SSC, 5 mL formamide, 200 μL 50× Denhardt solution, 10 mL 50 % dextran sulfate, and 50 mg yeast tRNA, and make up a final volume of 50 mL with RNase-free water.
13. DIG Wash and Block Buffer Set (Roche).
14. Anti-DIG-alkaline phosphatase antibody (Roche).
15. NBT/BCIP stock solution (Roche).

16. TE buffer: 10 mM Tris-HCL, 1 mM EDTA, adjust pH to approximately 8.
17. Humidity oven.

2.5 Materials for lncRNA Knockdown

2.5.1 lncRNA Knockdown Using siRNAs

1. siRNA targeting lncRNA of interest: sources of siRNAs include (1) ready-to-use Lincode RNA from <http://www.thermoscientificbio.com/>; (2) custom-designed siRNAs (*see* Note 2 for a list of siRNA design Web sites and Note 3 for a list of siRNA synthesis vendors).
2. Control siRNA (Thermo Scientific).
3. siRNA transfection reagents. We use Lipofectamine RNAiMAX from Invitrogen, but there are a handful of similar reagents that one can choose from. *See* Note 4 for a list of siRNA transfection reagents.
4. Opti-MEM.

2.5.2 lncRNA Knockdown Using shRNAs

1. pLKO.1 (Addgene).
2. shRNA (designed at <http://www.broadinstitute.org/rnai/public/seq/search>).
3. MISSION® pLKO.1-puro Non-Mammalian shRNA Control Plasmid DNA (Sigma).
4. pRSV-Rev (Addgene).
5. pMDLg/pRRE (Addgene).
6. pMD2G (Addgene).
7. HEK293T cells.

²List of siRNA design Web sites:

- a. siDESIGN center at <http://www.thermoscientificbio.com/>.
- b. BLOCK-iT™ RNAi Designer at <http://rnaidesigner.invitrogen.com/rnaiexpress/>.
- c. <http://www.broadinstitute.org/rnai/public/seq/search>.

³List of siRNA synthesis vendors:

- a. <http://www.idtdna.com/>.
- b. <http://www.invitrogen.com>.
- c. <http://www.genscript.com/>.
- d. <http://www.thermoscientificbio.com/>.
- e. <http://www.sigmaaldrich.com/>.

⁴List of siRNA transfection reagents:

- a. Lipofectamine RNAiMAX (Invitrogen).
- b. DharmaFECT Transfection Reagents (Thermo Scientific).
- c. X-tremeGENE siRNA transfection reagent (Roche).

8. RPMI 1640 media
9. Fetal Bovine serum.
10. Penicillin–Streptomycin solution with 10,000 U penicillin and 10 mg streptomycin/mL.
11. FuGENE6.
12. 0.45 μ m disk filter.
13. Hexadimethrine bromide (polybrene) (Sigma): to make 4 mg/mL stock, dissolve 40 mg powder in 10 mL Milli-Q water and filter through 0.22 μ m disk filter, make 500 μ L aliquots and store at -20°C .

3 Methods

The procedures must be performed in an RNase-free environment. Use filter tips and RNase-free tubes and clean all equipment and work surface with RNase ZAP before starting the experiment.

3.1 lncRNA-IP

lncRNA-IP aims to identify lncRNA species that bind to a protein of interest. The protocol includes two parts: (1) preparing protein lysate from target cells and (2) immunoprecipitating the protein of interest and extract protein-bound RNAs. It is up to the readers to decide the subsequent analysis on the isolated RNAs.

Before harvesting the cells, precool $1\times$ PBS, RNase-free water, nuclear isolation buffer, and RIP buffer on ice; estimate the amount of RIP buffer needed and add RNase inhibitor and protease inhibitor cocktail to the buffer accordingly (*see* Note 5).

3.1.1 Whole-Cell Lysate Preparation (See Note 6)—If nuclear RNA–protein interaction is the focus of the research, skip this step and go directly to Subheading 3.1.2 for nuclear lysate preparation.

1. Harvest cells using regular trypsinization technique and count the cell number.
2. Wash the cells in ice-cold $1\times$ PBS once and resuspend the cell pellet (1×10^7 cells) in 1 mL ice-cold RIP buffer containing RNase and protease inhibitors.
3. Shear the cells on ice using a Dounce homogenizer with 15–20 strokes.
4. Centrifuge at $15,000\times g$ for 15 min at 4°C and transfer the supernatant into a clean tube. This supernatant is the whole-cell lysate.

3.1.2 Cell Harvest and Nuclear Lysate Preparation (See Note 6)

1. Harvest cells using regular trypsinization technique and count the cell number.

⁵It is utterly important that the experiment described above be conducted with extra precaution to avoid RNA degradation. All materials have to be RNase-free and the buffers need to be precooled on ice.

⁶To ensure result reproducibility, the cells need to be maintained consistently.

2. Wash the cells in ice-cold $1\times$ PBS three times and resuspend 1×10^7 cells in 2 mL ice-cold PBS (*see* Note 7).
3. Put cell suspension in $1\times$ PBS on ice, add 2 mL ice-cold nuclear isolation buffer and 6 mL ice-cold RNase-free water into the tube and mix well. Incubate the cells on ice for 20 min with intermittent mixing (4–5 times).
4. Harvest nuclei by spinning the tube at $2,500\times g$ for 15 min at 4 °C. The pellet contains the purified nuclei.
5. Resuspend nuclei pellet in 1 mL freshly prepared ice-cold RIP buffer containing DTT, RNase, and protease inhibitors.
6. Shear the nuclei on ice with 15–20 strokes using a Dounce homogenizer.
7. Pellet nuclear membrane and debris by centrifugation at $16,000\times g$ for 10 min at 4 °C.
8. Carefully transfer the clear supernatant (nuclear lysate) into a new tube. The supernatant is nuclear lysate.

3.2 RNA Immune-Precipitation and Purification

1. Wash 40 μ L protein A/G beads with 500 μ L ice-cold RIP buffer three times. After the wash, spin down the beads at $600\times g$ for 30 s at 4 °C, take off the RIP buffer and add 40 μ L RIP buffer to resuspend the beads.
2. Add the prewashed beads and 5–10 μ g IgG into the whole-cell lysate from Subheading 3.1.1 or nuclear lysate from Subheading 3.1.2.
3. Incubate the lysate with IgG and beads at 4 °C with gentle rotation for 1 h. Pellet the IgG with beads by centrifugation at $16,000\times g$ for 5 min.
4. Carefully transfer the supernatant (pre-cleared nuclear lysate) into a new tube. At this point, the lysate can be divided into multiple portions of equal volume for different antibodies and corresponding controls. Take 50 μ L lysate and set aside on ice as input control.
5. Add antibody of interest into nuclear lysate (*see* Note 8). Incubate the lysate and antibody overnight at 4 °C with gentle rotation.
6. The next day, add 40 μ L prewashed protein A/G beads and incubate at 4 °C for 1 h with gentle rotation.
7. Pellet the beads by spinning at $600\times g$ for 30 s at 4 °C. Remove supernatant.
8. Wash the beads with 500 μ L ice-cold RIP buffer three times, invert 5–10 times during each wash and pellet the beads by spinning at $600\times g$ for 30 s at 4 °C.

⁷The abundance of different target proteins and lncRNAs may vary from cell line to cell line. Therefore, the amount of lysate input needs to be empirically determined for each assay. We found 1×10^7 cells is a good starting point. In some cases more cells are needed. Scale up the amount of buffer used to ensure high nuclear lysing efficiency.

⁸The amount of antibody used for each experiment need to be empirically determined. Our suggestion is to start at around 1–2 μ g antibody per million cells.

9. Wash the beads with 500 μ L ice-cold PBS and pellet the beads by spinning at $600 \times g$ for 30 s at 4 °C. Use a fine needle or tip to remove as much PBS as possible without disturbing the beads.
10. Resuspend the beads in 1 mL TRIzol RNA extraction reagent and isolate co-precipitated RNA according to manufacturer's instructions.
11. Dissolve RNA in nuclease-free water and store the RNA at -80 °C for further application (*see* Note 9).

3.3 lncRNA Pull-Down

lncRNA pull-down aims to identify proteins that bind to a lncRNA of interest. The protocol includes three parts: (1) synthesis and labeling the lncRNA of interest; (2) preparing protein lysate from target cells; (3) pull-down labeled lncRNA with its interacting proteins. The readers can decide the subsequent analyses on the lncRNA-bound proteins.

Before harvesting cells, precool PBS, water, RIP buffer, and NT2 buffer on ice; estimate the amount of buffers needed and add VRC, EDTA, DTT, RNase inhibitor, and protease inhibitor to the buffers accordingly (*see* Note 5).

3.3.1 Biotinylated RNA Synthesis by In Vitro Transcription

1. DNA template preparation: Linearize 3–4 μ g of the plasmid containing the desired template DNA (*see* Note 1) with a suitable restriction enzyme at the 3' end of the insert (*see* Note 10).
2. DNA template purification: run the digested DNA by DNA gel electrophoresis, excise the band of correct size, and extract DNA from agarose using Gel Extraction Kit.
3. In vitro synthesis of biotinylated RNA using T7 RNA polymerase: add the components listed in Table 1 into an RNase-free tube on ice and mix thoroughly. Centrifuge briefly and incubate at 37 °C for 2 h. After incubation, add 2 μ L Dnase I (RNase-free) into the reaction and incubate at 37 °C for 15 min to remove DNA template. Stop the reaction by adding 0.8 μ L 0.5 M EDTA (pH 8.0).
4. Biotinylated RNA purification of using G-50 Sephadex Columns: Before use, gently invert the column several times to resuspend the medium. Remove the top cap and then remove the bottom tip (*see* Note 11). Drain the buffer in the column by gravity and then centrifuge at $1,100 \times g$ for 2 min to eliminate residual buffer. Place the column in an upright position (*see* Note 12) with a new collection tube. Apply the RNA sample (up to 100 μ L) to the center of the column carefully (*see*

⁹The amount of nuclease-free water used to dissolve the RNAs is determined by several factors including the type of downstream analysis, the amount of lncRNA bound to the target protein and the cell type. We recommend the researchers start at 20 μ L and adjust according to their specific situations.

¹⁰Make sure the restriction enzyme digests efficiently and generate a 5' overhang.

¹¹The top-to-bottom sequence is necessary to avoid creating vacuum and uneven flow of buffer.

¹²Maintaining the column in an upright position is very important, especially after centrifugation. Tipping the column can cause backflow of the RNA sample and reduce the yield after purification.

Note 13) and centrifuge for 4 min at $1,100 \times g$ at 4°C . The elution contains the purified biotinylated RNA. Determine the RNA concentration and store at -80°C .

3.3.2 Whole-Cell Lysate Preparation (See Note 6)—If nuclear RNA–protein interaction is the focus of the research, skip this step and go directly to Subheading 3.2.3 for nuclear lysate preparation.

1. Harvest cell by regular trypsinization ($\sim 10^7$ cells) and wash cells with ice-cold $1\times$ PBS once.
2. Resuspend cell pellet in 1 mL ice-cold RIP buffer containing RNase and protease inhibitors.
3. Shear the cell pellet on ice using a Dounce homogenizer with 15–20 strokes.
4. Centrifuge at $15,000 \times g$ for 15 min at 4°C to clear the cell lysate. The supernatant contains whole-cell lysate.

3.3.3 Nuclear Lysate Preparation (See Note 6)

1. Cell harvest and nuclei isolation: harvest cells using regular trypsinization technique, wash cell pellet in ice-cold $1\times$ PBS once and resuspend 1×10^7 cells in 2 mL ice-cold $1\times$ PBS. Put cell suspension on ice, add 2 mL ice-cold nuclear isolation buffer and 6 mL ice-cold RNase-free water into the tube and mix well. Incubate the cells on ice for 20 min with intermittent mixing. Harvest nuclei by spinning the tube at $2,500 \times g$ for 15 min at 4°C . The pellet contains the purified nuclei.
2. Nuclei lysis: resuspend nuclei pellet in 1 mL freshly prepared ice-cold RIP buffer containing RNase and protease inhibitors. Shear the nuclei on ice with 15–20 strokes using a Dounce homogenizer. Pellet nuclear membrane and debris by centrifugation at $15,000 \times g$ for 15 min at 4°C . Carefully transfer the clear supernatant into a new tube. The supernatant contains nuclear lysate (*see* Note 7).
3. Pre-clear lysate: take 60 μL Streptavidin agarose beads slurry and wash the beads with pre-cold NT2 buffer three times. After wash, spin down the beads at $12,000 \times g$ for 1 min and resuspend the beads in 60 μL pre-cold NT2 buffer. Add the prewashed Streptavidin agarose beads into the whole-cell lysate (Subheading 3.2.2) or nuclear lysate (Subheading 3.2.3) and incubate at 4°C for at least 1 h with gentle rotation. Centrifuge the lysate briefly. Carefully transfer the supernatant into a new tube, and determine the protein concentration using BCA protein assay. Save 3–5 % of the lysate as input.

¹³Avoid to apply the sample to the side of the column or to overload the column, since it will reduce the yield and purity of the RNA.

3.3.4 RNA Pull-Down (See Note 14)

1. Dilute ~10 pmol biotinylated RNA into 40 μ L of RNA structure buffer and heat the tube at 90 °C for 2 min. Immediately transfer the tube on ice and incubate for another 2 min. Then let the tube sit at room temperature for 20 min to allow proper RNA secondary structure formation.
2. Add the properly folded RNA from previous step into 200 μ g of pre-cleared lysate from Subheading 3.2.4, and supplement with tRNA to a final concentration of 0.1 μ g/ μ L (see Note 15). Incubate at 4 °C for 2 h with gentle rotation.
3. Add 60 μ L prewashed Streptavidin agarose beads and incubate for 1 h at 4 °C.
4. At the end of the incubation, centrifuge at 12,000 $\times$ g 4 °C for 1 min and take off the supernatant. Wash the beads with 1 mL ice-cold NT2 buffer at 4 °C five times (see Note 16).
5. After the last wash, carefully remove any residual buffer without disturbing the beads.
6. Add 40 μ L 2 $\times$ Laemmli loading buffer and boil the beads in loading buffer for 5–10 min. Centrifuge at 12,000 $\times$ g for 1 min at room temperature and transfer the supernatant, which contain the lncRNA interacting proteins, into a new tube and store at –80 °C for further analysis.

3.4 lncRNA Northern Blot Analysis (See Note 17)

lncRNA northern blot analysis aims to characterize lncRNA expression. The protocol includes five parts: (1) RNA probe synthesis and labeling; (2) RNA sample electrophoresis; (3) RNA transfer; (4) RNA–probe hybridization; and (5) RNA–probe hybrid detection.

3.4.1 DIG-Labeled RNA Probe Synthesis by In Vitro Transcription—The DIG-labeled RNA probe synthesis is very similar to the biotinylated RNA synthesis described in Subheading 3.2.1. The differences between the two procedures are as follows:

1. Since the probe needs to be complement to the target sequence, the probe RNA is transcribed from the 3' end of the target sequence. We clone the gene of interest in reverse orientation to make the in vitro transcription template for northern probes.
2. Use DIG labeling mix in place of the biotin-labeling mix.

¹⁴The amount of total protein used in each assay need to be empirically determined based on the specific questions the researchers try to address. If the interaction between a specific lncRNA and a target protein is to be tested, the abundance of the target protein in the nuclear lysate needs to be taken into account to determine the amount of total protein used in the assay.

¹⁵The purpose of adding tRNA in the pull-down assay is to reduce nonspecific binding. Therefore, the amount of tRNA added to each reaction can be optimized according to specific conditions.

¹⁶We found that sometimes increasing the number of washes can greatly reduce the background. Therefore, it is recommended to optimize the wash condition for each specific assay.

¹⁷Northern blot analysis is a golden standard in RNA detection and analysis. There are many protocols developed by laboratories specialized in RNA research or companies. The protocol described here is adapted from the NorthernMax procedure from Invitrogen and DIG application manual for filter hybridization from Roche. In our hands, this protocol is time efficient and gives satisfying results without using radioactivity.

3.4.2 Separating RNA Samples by Electrophoresis

1. Wipe the gel rack, tray and combs with RNAZap, rinse with water and let dry. Weigh 100 g agarose in a clean glass flask and mix with 90 mL RNase-free water. Melt the agarose completely by heating with a microwave. Put the flask with melted agarose in a 55 °C water bath.
2. In a fume hood (*see* Note 18), add 10 mL 10× denaturing gel buffer to the gel mix that is equilibrated to 55 °C. Mix the gel solution by gentle swirling to avoid generating bubbles. Slowly pour the gel mix into the gel tray. Pop any bubbles or push them to the edges of the gel with a clean pipet tip. The thickness of the gel should be about 6 mm. Slowly place the comb in the gel. Allow the gel to solidify before removing the comb.
3. Right before RNA electrophoresis, place the gel tray in the electrophoresis chamber with the wells near the negative lead and add 1× MOPS gel running buffer in the chamber until it is 0.5–1 cm over the top of the gel (*see* Note 19).
4. Mix no more than 30 µg sample RNA with 3 volumes of RNA loading buffer (*see* Notes 20 and ²¹). To destruct any secondary structure of the RNAs, incubate the RNA with loading buffer at 65 °C for 15 min using a heat block. Spin briefly to collect samples to the bottom of the tube and put the tubes on ice (*see* Note 22).
5. Carefully draw the RNAs in the tip without trapping any bubbles at the end of pipet tip. Place the pipet tip inside of the top of the well, slowly push samples into the well and exit the tip without disturbing the loaded samples. If markers are needed, load one lane with DIG-labeled RNA marker.
6. Run the gel at 5 V/cm (*see* Note 23).
7. (Optional) Stain the gel with ethidium bromide and visualize the RNA under UV (*see* Note 24).

3.4.3 Transfer RNA from Agarose Gel to the Membrane (Fig. 3)

1. Use a razor blade to trim the gel by cutting through the wells and discard the unused gel above the wells. For marking the orientation, make a notch at a corner.

¹⁸Always cast the gel in a fume hood as the denaturing solution contains formaldehyde. Solidified gels can be wrapped up and stored at 4 °C overnight.

¹⁹Do not let gel soaked in running buffer for more than 1 h before loading.

²⁰Load no more than 30 µg total RNA in each lane. As the binding capacity of the membrane is limited, more RNA loaded does not guarantee a stronger signal. Overloading can lead to the detection of minor degradation of targeted RNAs.

²¹If the total volume of sample and dye exceed the capacity of the wells, it is necessary to concentrate the RNA by precipitation and to resuspend the pellet in smaller volume of water before adding the loading dye.

²²Use a heat block instead of a water bath to avoid contaminating the samples with water.

²³The voltage is decided by the distance between the two electrodes (not by the size of the gel). Usually, the run takes about 2 h. If the run is longer than 3 h, change the buffer at the two end chambers to avoid the pH gradient.

²⁴RNA gels stained with ethidium bromide are not suitable for northern blot analysis. Therefore, if a visual examination or photograph of total RNA samples is needed as a reference for the northern blot, we suggest the researchers to either run the same set of samples on a separate gel or stain with ethidium bromide the gel just for visualization; or de-stain the gel before continuing northern blot analysis. If a gel will be subjected to northern analysis after UV visualization, avoid prolonged exposure of the gel to UV light.

2. Cut the membrane to the size slightly larger than the gel. Make a notch at a corner to align the membrane with gel in the same orientation. Handle the membrane with care only touching the edges with gloved hands or blunt tip forceps.
3. Cut eight pieces of filter paper the same size of the membrane.
4. Cut a stack of paper towels that are 3 cm in height and 1–2 cm wider than the gel.
5. Pour 20× SSC into a flat-bottom container that has bigger dimension of the agarose gel. This serves as the buffer reservoir and can also be used to wet the paper and membrane. Put the reservoir on a support (i.e., a stack of books) so that its bottom is higher than the paper towel stack.
6. Cut three pieces of filter paper large enough to cover the gel and long enough to reach over to the reservoir. These papers serve as the bridge to transfer buffer from the reservoir to the gel.
7. Stack paper towel on a clean bench and put three pieces dry filter paper on top.
8. Wet two more pieces of filter paper and put on top of the dry filter paper. Gently roll out any bubbles between the filter paper layers.
9. Carefully put the membrane on top of the wet filter paper. Gently roll out bubbles between the membrane and the filter papers.
10. Put the trimmed gel onto the center of the membrane with the bottom of the gel touching the membrane (i.e., the gel plane that faces down during electrophoresis will be in contact with the membrane). Align the notches of the gel and the membrane. Roll out bubbles between the membrane and the gel.
11. Place three more pieces pre-wet filter paper on top of the gel and roll out bubbles between filter paper layers.
12. Wet the three pieces of paper bridge and place them with one end on top of the stack and the other end in buffer reservoir. Make sure there is no bubble between any layers of paper (*see* Note 25).
13. Place a 150–200 g object with the size similar to the gel on top of the stack.
14. Transfer the gel for 15–20 min/mm of gel thickness. It usually takes about 2 h (*see* Note 26).
15. RNA cross-link: disassemble the transfer stack carefully and rinse the member with 1× MOPS gel running buffer to remove residual agarose. Blot off excessive liquid and immediately subject the membrane to cross-link treatment. Cross-link the RNA to the membrane with Stratalinker® UV Crosslinker using the autocrosslink setting (*see* Note 27). Air-dry the membrane at room temperature. At this point, the

²⁵It is essential to ensure that the only way for the transfer buffer to run from reservoir to the dry paper stack is through the gel. Therefore, extra care is needed to assemble the stack properly to avoid shortcut. The most common shortcut happens between the bridge and the paper beneath the gel. One can cover the edges of the gel with Parafilm to prevent this from happening.

²⁶Transfers longer than 4 h may cause small RNA hydrolysis and reduce yield.

²⁷The autocrosslink Mode of Stratalinker® UV Crosslinker delivers a preset exposure of 1,200 µJ to the membrane and takes about 40 s. Other methods of cross-linking RNA to membrane are available and can be used at this step as well.

membrane can be subjected to hybridization immediately or stored in a sealed bag between two pieces filter paper at 4 °C for several months before hybridization.

3.4.4 Hybridization of DIG-Labeled Probes to the Membrane (See Note 28)

1. Pre-hybridization: Reconstitute the DIG Easy Hyb Granules: add 64 mL RNase-free water into one bottle of the DIG Easy Hyb Granules, stir for 5 min at 37 °C to complete dissolve the granules. DIG Easy Hyb buffer will be used in pre-hybridization and hybridization. The reconstituted DIG Easy Hyb buffer is stable at room temperature for up to 1 month. For every 100 cm² membrane, 10–15 mL Hyb buffer should be used for pre-hybridization. Measure the appropriate amount of Hyb buffer for pre-hybridization and place it in a clean tube and pre-warm it in a 68 °C water bath (*see* Note 29). Put the membrane in a hybridization bag, add the pre-warmed Hyb buffer from the previous step, seal the bag properly and incubate the membrane in Hyb buffer at 68 °C for at least 30 min with gentle agitation (*see* Note 30). Pre-hybridization can be up to several hours as far as the membrane remains wet.
2. Hybridization: For every 100 cm² membrane, 3.5 mL Hyb buffer is needed for hybridization. Measure the appropriate amount of Hyb buffer for hybridization and place it in a clean tube and pre-warm it in a 68 °C water bath (*see* Note 29). Determine the amount of RNA probe needed (*see* Note 31) and place it into a microcentrifuge tube with 50 µL RNase-free water. Denature the probe by heating the tube at 85 °C for 5 min and chill on ice immediately. Mix the denatured probe with pre-warmed Hyb buffer by inversion. Remove pre-hybridization buffer from the membrane and immediately replace with the pre-warmed hybridization buffer containing the probe. Seal the bag properly and incubate the membrane in probe-containing Hyb buffer at 68 °C overnight with gentle agitation (*see* Note 30).
3. The next day, pre-warm the High Stringency Buffer to 68 °C and pour Low Stringency Buffer in an RNase-free container at room temperature and make sure it is enough to cover the membrane.
4. Cut open the hybridization bag, remove the Hyb buffer, and immediately submerge the membrane in the Low Stringency Buffer.
5. Wash the membrane twice in Low Stringency Buffer at room temperature for 5 min each time with shaking.
6. Wash the membrane twice in High Stringency Buffer at 68 °C for 5 min each time with shaking (*see* Note 32).

²⁸Once the membrane is wet during pre-hybridization, it is important to avoid it getting dry during the hybridization and detection process. Dried membrane will have high background. Only if the membrane will not be stripped and reprobed, it can be dried after the last high stringency wash and stored at 4 °C for future analysis.

²⁹For most northern blot hybridization using DIG Easy Hyb buffer, 68 °C is appropriate for both pre-hybridization and hybridization. In cases of more heterologous RNA probes being used, the pre-hybridization and hybridization temperatures need to be optimized.

³⁰Pre-hybridization/hybridization can be performed in containers other than bags, as far as it can be tightly sealed. Sealing the hybridization container can prevent the release of NH₄, which changes the pH of the buffer during incubation.

³¹For RNA probe synthesized by in vitro transcription, it is recommended that the probe concentration should be 100 ng/mL Hyb buffer.

3.4.5 Detection of DIG-Probe–Target RNA Hybrids

1. Localizing the probe–target hybrid with anti-DIG antibody. Transfer the membrane from the last wash in High stringency buffer to a plastic container with 100 mL washing buffer. Incubate for 2 min at room temperature and discard the washing buffer. Add 100 mL Blocking buffer onto the membrane and incubate for more than 30 min (up to 3 h) with shaking at room temperature. Dilute anti-DIG-alkaline phosphatase antibody at the ratio of 1:5,000 in Blocking buffer and incubate the membrane in 20 mL diluted antibody for 30 min at room temperature with shaking. Wash the membrane twice with 100 mL of washing buffer for 15 min each time at room temperature.
2. Visualizing probe–target hybrids using chromogenic or chemiluminescent method (*see* Note 33): Equilibrate the membrane in 20 mL Detection buffer for 3 min at room temperature. If using the chromogenic method, prepare the color substrate solution while equilibrating the membrane. Put the membrane with the RNA side facing up in a container and incubate in 10 mL color substrate solution in the dark without shaking. When the desired intensity for the band is observed, discard the color substrate solution and rinse the membrane in 50 mL of TE buffer for 5 min (*see* Note 34). Document the result by photographing the membrane (*see* Note 35). For chemiluminescent detection: put the membrane with the RNA side facing up on a plastic sheet (i.e., cut out of a hybridization bag) and add 20 drops of CDP-Star, Ready-to-Use reagent. Immediately cover the membrane with another sheet to evenly distribute the reagent without creating any bubbles. Incubate for 5 min at room temperature. Squeeze out excess reagent and seal the bag. Develop the membrane with an X-ray film in a dark room (*see* Note 35).

3.5 lncRNA In Situ Hybridization

lncRNA in situ hybridization aims to characterize and quantify lncRNA expression in cells. The protocol includes three parts: (1) RNA probe synthesis and labeling; (2) cell preparation and pretreatment; (3) RNA–probe hybridization and detection.

3.5.1 DIG-Labeled RNA Probe Synthesis by In Vitro Transcription—The DIG-labeled RNA probe synthesis is very similar to the biotinylated RNA synthesis described in Subheading 3.2.1. The differences between the two procedures are as follows:

1. Both sense and antisense probes need to be synthesized (*see* Note 36). The antisense probe contains the complementary sequence to the target gene and the

³²If the probe is less than 80 % homologous to the target RNA, the high stringency wash should be performed at a lower temperature, which needs to be empirically determined.

³³The DIG probe–target RNA hybrids can be detected in two ways. One uses chemiluminescent method, whereas the other uses chromogenic method. The chemiluminescent method is sensitive and fast, but it requires the usage of the films and the accessibility of a darkroom. The chromogenic method requires no film or dark room and different targets can be detected simultaneously using different colored substrate. However, the chromogenic method may not be sensitive enough for low-abundant targets.

³⁴At this step, if there are multiple membranes, process one at a time. Depending on the abundance of target RNAs, the band may appear as quickly as a few minutes after adding the chromogenic agents. The reaction can be stopped when the band reaches a desired intensity.

³⁵If reprobing is needed, photograph the result while the membrane is wet and proceed to stripping and reprobing. If no reprobing is needed, dry the membrane, document the result by photograph and store the dried membrane in a clean bag at room temperature.

sense probe contains the target gene sequence. The hybridization signal from the antisense probe represents target gene expression while the sense probe is used as negative control.

2. To generate antisense probes, we clone the gene of interest in reverse orientation and transcribe it using in vitro transcription as described in Subheading 3.2.1.
3. DIG labeling mix is used in place of the biotin-label mix during in vitro transcription.

3.5.2 Cell Preparation and Pretreatment

1. Culture the cells of interest on multi-well chamber glass slides. At the day of experiment, the cells should be 60–80 % confluent. We use the 8-chamber glass slide to reduce the amount of hybridization buffer and probes used. The amount of reagents used in the following protocol is for 8-well chamber slides. Scale up or down according to the cell culture device used in each specific experiment.
2. On the day of the experiment, wash the cells with 400 μ L 1 $\times$ RNase-free-PBS per well, then fix the cells using 200 μ L 4 % PFA per well at room temperature for 10 min. Wash the fixated cells three times with 1 $\times$ PBS at room temperature.
3. Add acetic anhydride into 0.1 M triethanolamine to make the final acetic anhydride concentration 0.25 % (v/v, *see* Note 37). Pre-treat cells with 0.1 M triethanolamine containing 0.25 % acetic anhydride for 10 min at room temperature. Wash the cells with 1 $\times$ PBS for 5 min afterwards.
4. Permeabilize the cells with 0.2 M HCl for 10 min and wash the cells twice with 1 $\times$ PBS, 5 min each time, at room temperature.
5. The slides can be either subject to hybridization immediately or stored in 1 $\times$ PBS at 4 °C for a couple of days before proceeding to the next step.

3.5.3 In Situ Hybridization and Detection of Probe–Target Hybrid

1. Add 200 μ L pre-hybridization buffer (hybridization buffer without probe and dextran sulfate, *see* Subheading 2 for details) into each well. Incubate at 60 °C for 2 h (*see* Note 38).
2. During pre-hybridization, take the amount of probe needed for the experiment (*see* Note 39) and denature the probes by heating them at 85 °C for 10 min and immediately cool down on ice for at least 5 min.

³⁶During assay development for each specific gene target, it is critical to know whether the hybridization is specific to the gene of interest. One way to ensure hybridization specificity is to include samples hybridizing with sense probe (containing the target sequence, serving as negative controls) at the same concentration as those with the antisense probe (containing the complementary sequence). If the control probe gives comparable signal as the target probe does, the hybridization may not be specific enough to the gene of interest. In this case, optimization of the probe sequence, probe concentration, hybridization condition, and wash stringency will be needed.

³⁷The acetic anhydride needs to be added freshly each time and discard any leftover 0.1 M triethanolamine with acetic anhydride.

³⁸To avoid evaporation of the buffer, we put on the lid for the chamber slide, and use the humidity oven with temperature set at 60 °C for the incubation period.

³⁹The concentrations of different probes need to be empirically determined. We found that 100–400 ng probes per mL hybridization buffer are a good starting point.

3. Add denatured probes into the hybridization buffer. To ensure assay specificity, always use a control probe for each target probe, *see* Note 36 for details.
4. Remove the pre-hybridization buffer from chambers and add 200 μ L hybridization buffer containing denatured probes on to the slide and incubate at 60 °C in humidity oven with lid on overnight.
5. The next day, wash the cells by adding 500 μ L 0.1 $\times$ SSC with 50 % formamide in each well and incubate the slides with lid at 60 °C for 30 min twice (*see* Note 40).
6. Then wash the cells by adding 500 μ L 2 $\times$ SSC to each well and incubate for 5 min at room temperature twice (*see* Note 40).
7. Wash the cells with 500 μ L washing buffer per well at room temperature for 5 min.
8. Add 200 μ L blocking buffer per well and incubate for 1 h at room temperature.
9. While the cells are incubated with blocking buffer, dilute the anti-DIG-alkaline phosphatase antibody in blocking buffer (*see* Note 41).
10. Discard the blocking buffer. Add 100 μ L diluted antibody per well and incubate for 1 h at room temperature.
11. Wash the slides with 500 μ L wash buffer per well for 15 min at room temperature twice.
12. Incubate the slides in 500 μ L detection buffer per well for 10 min at room temperature. Meanwhile, dilute 200 μ L NBT/BCIP stock solution in 10 mL detection buffer.
13. Discard the detection buffer and add 500 μ L diluted NBT/BCIP solution per well and incubate cells in the dark (up to 16 h).
14. When the desired color intensity is observed (*see* Note 42), stop the color reaction by discarding the NBT-BCIP solution and incubate with TE buffer for 15 min.

3.6 shRNA Knockdown

Like mRNAs, the endogenous lncRNA expression can be down-regulated using two RNA silencing-mediated approaches. One is transfecting small-interfering RNAs (siRNAs) targeting the gene of interest into cells. The other is stably expressing gene-specific RNA hairpins (shRNAs) in target cells. The siRNA approach provides acute gene down-regulation and allows gradient knockdown of target gene expression by adding different amounts of siRNAs; whereas the shRNA-approach provides sustained down-regulation of the target lncRNA, making it more suitable for experiments that take a long period to get the end-point readout. The following section will provide protocols for both methods.

⁴⁰The wash conditions can be optimized by adjusting the salt concentration and the temperature.

⁴¹The recommended range for anti-DIG antibody is from 1:500 to 1:2,000. The optimal concentration needs to be empirically determined.

⁴²The process usually takes from 5 min to 2 h. Stop the reaction once the desired signal is visible.

3.6.1 lncRNA Knockdown Using siRNAs—The following protocol provides siRNA concentration and the amount of transfection reagents based on Lipofectamine RNAiMAX transfection protocol. If you are using different transfection reagents, please follow the specific instructions from the manufacturers.

1. Make 20 μ M siRNA stock solution with RNase-free water, aliquot into 20 μ L per tube and store at -80°C . It is highly recommended to reduce the freeze–thaw cycles of siRNA stocks.
2. The day before transfection, plate cells in 24-well plate so that it will be 60–80 % confluent the next day.
3. On the day of transfection, calculate the amount of control and targeting siRNAs needed for each well according to Table 2 (*see* Note 43). Dilute the siRNA and transfection reagents in Opti-MEM in separate tubes. Mix together and incubate at room temperature for at least 20 min.
4. Without removing any media from the wells, add the siRNA and transfection reagent mixture to the wells.
5. Incubate the cells with siRNA/transfection reagents for at least 6 h (*see* Note 44).
6. Remove the media containing siRNA/transfection reagents and feed the cells with fresh media.
7. Harvest the infected cells in Trizol, 48–72 h post-transfection.
8. Check target gene knockdown efficiency by quantitative RT-PCR of RNA from control and targeting siRNA transfected cells.

3.6.2 lncRNA Knockdown Using shRNAs

1. To generate shRNA knockdown constructs: design shRNA sequence targeting specific lncRNA at <http://www.broadinstitute.org/rnai/public/seq/search> (*see* Note 45). Synthesize the DNA containing the shRNA sequence of choice and clone it into lentiviral vector pLKO.1. Purify pLKO.1 constructs (containing specific shRNA or scramble controls) and other packing constructs (pRSV-Rev and pMDLg/pRRE) using QIAGEN Plasmid *Plus* Maxi Kit (*see* Note 46).
2. Packing virus using 293T cells: plate HEK293T cells in 6-well plate the day before transfection so it will be 80 % confluent the next day. Re-feed cells with antibiotic-free media before transfection. Mix 4 μ g plasmid cocktail and 12 μ L FuGENE6 transfection reagent according to the FuGENE protocol. The composition of the plasmid cocktail is shown in Table 3: add the FuGENE:DNA mixture onto cells. Eight hours after transfection, change into regular media with antibiotics. Forty-eight hours after transfection, harvest virus by collecting the culture media and

⁴³The amounts of siRNA and transfection reagents for each cell line need to be empirically determined.

⁴⁴Leaving the transfection reagents on cells for extended period of time may cause cell toxicity.

⁴⁵It is common to clone five or more shRNA and choose the two that gives the highest knockdown efficiency for future analysis.

⁴⁶We prefer to use the Qiagen Plasmid *Plus* Maxi Kit. However, any plasmid isolation kit that gives high quality DNA for efficient transfection can be used. A good mini-prep kit can be also used to isolate small amount plasmid during pilot experiments.

filter through 0.45 µm disk filter to get rid of cell debris. The virus stock can be aliquoted and stored at –80 °C for future use.

3. Cell infection: plate target cells in 6-well plate the day before infection so that it will be 50–60 % confluency the next day. Mix three parts of virus with one part of culture media (i.e., 3 mL virus with 1 mL medium) and add polybrene to final concentration of 8 µg/mL. Add virus mixture directly onto cells and incubate overnight.
4. After 24 h of incubation, change media or split cells depending on the cell confluency.
5. Harvest the infected cells in Trizol 72–96 h postinfection.
6. Check target gene knockdown efficiency by quantitative RT-PCR of RNA from scrambled and shRNA-infected cells.

Acknowledgments

This work was supported, in whole or in part, by National Institutes of Health Grant R01CA142776 (L. Zhang), Ovarian Cancer SPORE P50-CA83638-7951 Project 3 (L. Zhang), Department of Defense Grant W81XWH-10-1-0082 (L. Zhang), the Ovarian Cancer Research Fund Tilberis Scholar Award the Bassett Research Center grant for BRCA (L. Zhang), and Marsha Rivkin Center for Ovarian Cancer Research (L. Zhang). D. Zhang was supported by the China Scholarship Council.

References

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011; 144:646–674. [PubMed: 21376230]
2. International Human Genome Sequencing, C. Finishing the euchromatic sequence of the human genome. *Nature*. 2004; 431:931–945. [PubMed: 15496913]
3. Djebali S, Davis CA, Merkel A, et al. Landscape of transcription in human cells. *Nature*. 2012; 489:101–108. [PubMed: 22955620]
4. Rinn JL, Chang HY. Genome regulation by long noncoding RNAs. *Annu Rev Biochem*. 2012; 81:145–166. [PubMed: 22663078]
5. Lee JT. Epigenetic regulation by long noncoding RNAs. *Science*. 2012; 338:1435–1439. [PubMed: 23239728]
6. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. *Cancer Discov*. 2011; 1:391–407. [PubMed: 22096659]
7. Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. *Nature*. 2012; 482:339–346. [PubMed: 22337053]
8. Spizzo R, Almeida MI, Colombatti A, et al. Long non-coding RNAs and cancer: a new frontier of translational research? *Oncogene*. 2012; 31:4577–4587. [PubMed: 22266873]
9. Pachnis V, Brannan CI, Tilghman SM. The structure and expression of a novel gene activated in early mouse embryogenesis. *EMBO J*. 1988; 7:673–681. [PubMed: 3396539]
10. Bartolomei MS, Zemel S, Tilghman SM. Parental imprinting of the mouse H19 gene. *Nature*. 1991; 351:153–155. [PubMed: 1709450]
11. Brown CJ, Ballabio A, Rupert JL, et al. A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. *Nature*. 1991; 349:38–44. [PubMed: 1985261]
12. Kapranov P, Cawley SE, Drenkow J, et al. Large-scale transcriptional activity in chromosomes 21 and 22. *Science*. 2002; 296:916–919. [PubMed: 11988577]
13. Rinn JL, Euskirchen G, Bertone P, et al. The transcriptional activity of human chromosome 22. *Genes Dev*. 2003; 17:529–540. [PubMed: 12600945]

14. Rinn JL, Kertesz M, Wang JK, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. *Cell*. 2007; 129:1311–1323. [PubMed: 17604720]
15. Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. *Nature*. 2010; 464:1071–1076. [PubMed: 20393566]
16. Guttman M, Amit I, Garber M, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. *Nature*. 2009; 458:223–227. [PubMed: 19182780]
17. Khalil AM, Guttman M, Huarte M, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. *Proc Natl Acad Sci U S A*. 2009; 106:11667–11672. [PubMed: 19571010]
18. Maeda N, Kasukawa T, Oyama R, et al. Transcript annotation in FANTOM3: mouse gene catalog based on physical cDNAs. *PLoS Genet*. 2006; 2:e62. [PubMed: 16683036]
19. Jia H, Osak M, Bogu GK, et al. Genomewide computational identification and manual annotation of human long noncoding RNA genes. *RNA*. 2010; 16:1478–1487. [PubMed: 20587619]
20. Orom UA, Derrien T, Beringer M, et al. Long noncoding RNAs with enhancer-like function in human cells. *Cell*. 2010; 143:46–58. [PubMed: 20887892]
21. Prensner JR, Iyer MK, Balbin OA, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. *Nat Biotechnol*. 2011; 29:742–749. [PubMed: 21804560]
22. Cabili MN, Trapnell C, Goff L, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. *Genes Dev*. 2011; 25:1915–1927. [PubMed: 21890647]
23. Derrien T, Johnson R, Bussotti G, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. *Genome Res*. 2012; 22:1775–1789. [PubMed: 22955988]
24. Brown CJ, Hendrich BD, Rupert JL, et al. The human XIST gene: analysis of a 17 kb inactive X-specific RNA that contains conserved repeats and is highly localized within the nucleus. *Cell*. 1992; 71:527–542. [PubMed: 1423611]
25. Zhao J, Sun BK, Erwin JA, et al. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. *Science*. 2008; 322:750–756. [PubMed: 18974356]
26. Jeon Y, Lee JT. YY1 tethers Xist RNA to the inactive X nucleation center. *Cell*. 2011; 146:119–133. [PubMed: 21729784]
27. Tsai MC, Manor O, Wan Y, et al. Long noncoding RNA as modular scaffold of histone modification complexes. *Science*. 2010; 329:689–693. [PubMed: 20616235]
28. Yap KL, Li S, Munoz-Cabello AM, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. *Mol Cell*. 2010; 38:662–674. [PubMed: 20541999]
29. Kotake Y, Nakagawa T, Kitagawa K, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. *Oncogene*. 2011; 30:1956–1962. [PubMed: 21151178]
30. Huarte M, Guttman M, Feldser D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. *Cell*. 2010; 142:409–419. [PubMed: 20673990]
31. Grote P, Wittler L, Hendrix D, et al. The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. *Dev Cell*. 2013; 24:206–214. [PubMed: 23369715]
32. Kino T, Hurt DE, Ichijo T, et al. Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. *Sci Signal*. 2010; 3:8.
33. Hung T, Wang Y, Lin MF, et al. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. *Nat Genet*. 2011; 43:621–629. [PubMed: 21642992]
34. Tripathi V, Ellis JD, Shen Z, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. *Mol Cell*. 2010; 39:925–938. [PubMed: 20797886]

35. Bernard D, Prasanth KV, Tripathi V, et al. A long nuclear-retained non-coding RNA regulates synaptogenesis by modulating gene expression. *EMBO J.* 2010; 29:3082–3093. [PubMed: 20729808]
36. Tripathi V, Shen Z, Chakraborty A, et al. Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. *PLoS Genet.* 2013; 9:e1003368. [PubMed: 23555285]
37. Salmena L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? *Cell.* 2011; 146:353–358. [PubMed: 21802130]
38. Kim TK, Hemberg M, Gray JM, et al. Widespread transcription at neuronal activity-regulated enhancers. *Nature.* 2010; 465:182–187. [PubMed: 20393465]
39. Wang D, Garcia-Bassets I, Benner C, et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. *Nature.* 2011; 474:390–394. [PubMed: 21572438]
40. Melo CA, Drost J, Wijchers PJ, et al. eRNAs are required for p53-dependent enhancer activity and gene transcription. *Mol Cell.* 2013; 49:524–535. [PubMed: 23273978]
41. Lai F, Orom UA, Cesaroni M, et al. Activating RNAs associate with mediator to enhance chromatin architecture and transcription. *Nature.* 2013; 494:497–501. [PubMed: 23417068]
42. Ji P, Diederichs S, Wang W, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. *Oncogene.* 2003; 22:8031–8041. [PubMed: 12970751]
43. Yang F, Huo XS, Yuan SX, et al. Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. *Mol Cell.* 2013; 49:1083–1096. [PubMed: 23395002]
44. Loewer S, Cabili MN, Guttman M, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. *Nat Genet.* 2010; 42:1113–1117. [PubMed: 21057500]
45. Guttman M, Donaghey J, Carey BW, et al. lincRNAs act in the circuitry controlling pluripotency and differentiation. *Nature.* 2011; 477:295–300. [PubMed: 21874018]
46. Kretz M, Siprashvili Z, Chu C, et al. Control of somatic tissue differentiation by the long non-coding RNA TINCR. *Nature.* 2013; 493:231–235. [PubMed: 23201690]
47. Zhang A, Zhou N, Huang J, et al. The human long non-coding RNA-RoR is a p53 repressor in response to DNA damage. *Cell Res.* 2013; 23:340–350. [PubMed: 23208419]
48. Pasmant E, Laurendeau I, Heron D, et al. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. *Cancer Res.* 2007; 67:3963–3969. [PubMed: 17440112]
49. Yildirim E, Kirby JE, Brown DE, et al. Xist RNA is a potent suppressor of hematologic cancer in mice. *Cell.* 2013; 152:727–742. [PubMed: 23415223]
50. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. *Cancer Res.* 1999; 59:5975–5979. [PubMed: 10606244]
51. Lee GL, Dobi A, Srivastava S. Prostate cancer: diagnostic performance of the PCA3 urine test. *Nat Rev Urol.* 2011; 8:123–124. [PubMed: 21394175]

Fig. 1.

Schematic diagram of lncRNA gene organization and mechanistic themes. **(a)** lncRNA gene organization in human genome. Two types of lncRNA genes exist in the genome. Intergenic lncRNA genes (*red bar, upper panel*) have no overlap with other protein-coding genes (*blue bar, upper panel*). Genic lncRNA genes (*red bar, lower panel*) are overlapping with protein coding genes (*blue bar, upper panel*) in various fashions. **(b)** lncRNAs can either function as scaffolds via RNA–protein interaction (*upper panel*), or as guides via RNA–protein and RNA–DNA interactions (*lower panel*)

Fig. 2. Schematic diagram of lncRNA IP and lncRNA pull-down. **(a)** lncRNA IP, to identify lncRNA molecules interacting with a protein of interest. **(b)** lncRNA pulldown, to identify proteins interacting with a specific lncRNA

Fig. 3.
Schematic diagram of downward transfer of northern blot analysis (adapted from NorthernMax kit instruction, Invitrogen)

Table 1Components for in vitro transcription of template DNA (20 μ L system)

Linearized plasmid DNA (1 μg) or PCR product (100–200 ng)	
Biotin RNA labeling mix (10 $\times$)	2 μ L
5 $\times$ Transcription buffer	4 μ L
T7 RNA polymerase (20 U/ μ L)	2 μ L
RNase-free sterile water	Up to 20 μ L

Table 2

siRNA transfection components and composition

Reagent per well for 24-well plate	Amount of reagent
Opti-MEM for siRNA dilution	50 μ L
siRNA	0.6–30 pmol
Opti-MEM for RNAiMAX dilution	50 μ L
RNAiMAX	0.5–1.5 μ L

Table 3

Plasmid composition for pLKO.1 virus packaging

Plasmid	µg
pRSV-Rev	0.65
pMDLg/pRRE	1.3
pMD2G	0.65
pLKO.1	1.4